# Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge

> **NCT06303128** · PHASE3 · RECRUITING · sponsor: **James Tarbox, MD** · enrollment: 380 (estimated)

## Conditions studied

- Penicillin Allergy

## Interventions

- **DRUG:** Amoxicillin 250 MG
- **DRUG:** Placebo
- **DRUG:** Amoxicillin 62.5mg
- **DRUG:** Amoxicillin 187.5mg

## Key facts

- **NCT ID:** NCT06303128
- **Lead sponsor:** James Tarbox, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-03
- **Primary completion:** 2026-07
- **Final completion:** 2026-12
- **Target enrollment:** 380 (ESTIMATED)
- **Last updated:** 2025-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06303128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06303128, "Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06303128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*